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Background: This research is a one-site neuroimaging component of a two-site genetic study involving patients
with schizophrenia at early and later stages of illness. Studies support a role for the neuronal Per-Arnt-Sim 3 (NPAS3)
gene in processes that are essential for normal brain development. Specific NPAS3 variants have been observed at
an increased frequency in schizophrenia. In humans, NPAS3 protein was detected in the hippocampus from the first
trimester of gestation. In addition, NPAS3 protein levels were reduced in the dorsolateral prefrontal cortex of some
patients with schizophrenia. Npas3 knockout mice display behavioural, neuroanatomical and structural changes with
associated severe reductions in neural precursor cell proliferation in the hippocampal dentate gyrus. This study will
evaluate the hypothesis that the severe reductions in neural precursor cell proliferation in the dentate gyrus will be
present to some degree in patients carrying schizophrenia-associated NPAS3 variants and less so in other patients.
Methods/Design: Patients enrolled in the larger genetic study (n = 150) will be invited to participate in this
neuroimaging arm. The genetic data will be used to ensure a sample size of 45 participants in each genetic
subgroup of patients (with and without NPAS3 variants). In addition, we will recruit 60 healthy controls for
acquisition of normative data. The following neuroimaging measures will be acquired from the medial temporal
region: a) an index of the microcellular environment; b) a macro-structural volumetric measure of the hippocampus;
and c) concentration levels of N-acetylaspartate, a marker of neuronal health.
Discussion: This study will help to establish the contribution of the NPAS3 gene and its variants to brain tissue
abnormalities in schizophrenia. Given the genetic and phenotypic heterogeneity of the disorder and the large
variation in outcomes, the identification of biological subgroups may in future support tailoring of treatment
approaches in order to optimize recovery.
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Rationale
Psychotic disorders, including schizophrenia, are among
the most devastating of all medical conditions in terms
of personal suffering, disability, and costs to society. The
personal suffering combined with the rising costs associ-
ated with this illness underscore the necessity of better
understanding the biological underpinnings of psychotic
disorders. This improved understanding should facilitate
the development, implementation and evaluation of* Correspondence: dcbernie@dal.ca
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unless otherwise stated.more effective and targeted treatment and rehabilita-
tion programs.
With onset typically occurring during adolescence or
early adulthood, schizophrenia is characterized by posi-
tive symptoms (delusions, hallucinations, disorganization
of thought and behavior), negative symptoms (poverty of
thought and affect, apathy and emotional withdrawal), in
addition to cognitive symptoms (deficits in working
memory and executive function). Even following treat-
ment, significant residual symptoms may persist indefin-
itely, entailing a level of social and occupational disability.
As a result of the early age of onset and the long term dis-
ability that can arise, the World Health Organization
(WHO) proclaimed schizophrenia as ‘youth’s greatest
disabler’. Despite increasing evidence for a host ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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schizophrenia, a full understanding of the biological
underpinnings of this illness remains elusive [1]. A bet-
ter understanding of how neurobiological, genetic and
functional features of schizophrenia are linked together
is essential in order to facilitate early identification of
the illness, effective treatment, reduction of social and
personal costs, and decreased disability.
Schizophrenia candidate genes
Suggested candidate genes include, but are not limited
to, neuregulin 1 (NRG1), disrupted in schizophrenia-1
(DISC1), and catechol-1-methyltransferase (COMT) [2].
Despite strong support for the involvement of some
genes, no defect in a single gene and no pattern of de-
fects in a small set of genes have been identified as con-
tributors to the majority of schizophrenia cases. Studies
on European, African-American, Japanese and Chinese
populations suggest that varied combinations of quite
large numbers of genes likely contribute to the onset and
development of schizophrenia, and that the specific gene
combinations may differ with respect to ethnicity [3-5].
Identification of a candidate gene for schizophrenia
Two research groups identified a Scottish family in
which a mother and two daughters were affected with
schizophrenia and carried a chromosome translocation, t
(9;14)(q34:q13) [6,7]. Flow-sorted chromosomes from
both mother and one available daughter were used to
map a translocation breakpoint between the markers
D14S730 and D14S70, a 683 kb interval at chromosome
14q13. Further molecular studies indicated that this
breakpoint disrupted the neuronal Per-Arnt-Sim 3 (NPAS3)
gene, indicating a potential causative or contributory role
to schizophrenia [6]. Nuclear localization of a green fluor-
escent (GFP)-labeled NPAS3 protein was observed, which
was expected, as NPAS3 is a member of a family of tran-
scription factors [8]. Npas3 gene expression in the mouse is
found mainly in the central nervous system, particularly in
the neural tube, neuroepithelium and cortex [8,9].
Since the initial discovery, other groups have contin-
ued to explore the role of NPAS3 in nervous system de-
velopment. During human embryogenesis, NPAS3 can
be detected as early as the first trimester in numerous
regions including the hippocampus and cerebellum [10].
MicroRNA control is characteristic of genes required for
brain development, and NPAS3 is regulated post-natally
by the microRNA miR-17 [11]. A search for genes con-
trolled by NPAS3 has revealed pathways associated not
only with neurogenesis, but also with glycolysis [12].
From an evolutionary perspective, the NPAS3 gene
was found to contain a ‘human accelerated region’,
HAR21 [13]. Further studies revealed fourteen ‘human
accelerated elements’ or HAEs associated with the gene,the largest cluster in the human genome [14]. These
DNA elements are implicated in the development of
human-specific traits, including brain evolution and
function. Zebrafish studies indicate that many of the
NPAS3-associated HAEs act as transcriptional enhancers
of NPAS3 expression during nervous system develop-
ment, leading to the suggestion that they may influence
spatio-temporal expression of NPAS3 in the human
brain throughout development [14].
These studies provide further support for our hypothesis
that NPAS3 influences brain structure and activity from
the very earliest stages of human brain development.
NPAS3 variants in schizophrenia
NPAS3 is comprised of twelve relatively short exons sep-
arated by large introns [6,7]. By full sequencing of all
exons of the NPAS3 coding region (sequenced individu-
ally), we identified two exons with differences from the
published sequence. These two exons were subsequently
sequenced in a cohort of 83 individuals with schizophre-
nia, compared to 83 controls [15].
Our case–control study identified significant changes
in the NPAS3 coding sequence with a positive associ-
ation to schizophrenia. Three NPAS3 variants occurred
at a higher frequency in the patient group, and were in
linkage disequilibrium in the vast majority of cases
(rs12434716, p = 0.009; rs10141940 and rs10142034 both
at p = 0.01). A variety of programs were used to predict
the potential impact of the variants on NPAS3 gene ex-
pression or protein function, including Sorting Intoler-
ant from Tolerant (SIFT) to identify conserved amino
acids function [16], Exon Splice Enhancer (ESE) Finder to
locate putative motifs that regulate splicing [17,18], and
NetPhos to identify potential phosphorylation motifs. The
allele frequency of NPAS3 single-nucleotide polymorph-
ism (SNP) rs12434716 results in an amino acid change
(p.Ala552Pro) and may influence the activity of NPAS3
protein. While the remaining SNPs are synonymous,
some are located in exon splice enhancer motifs and may
affect splicing. Thus, some of the SNPs may affect NPAS3
function directly or be in linkage disequilibrium with the
disease, causing change elsewhere in the gene [15].
Further support for NPAS3 variation in brain dysfunction
came from a separate and concomitant case–control study
using larger cohorts of individuals with schizophrenia (n =
386) or bipolar disorder (n = 368). Linkage-disequilibrium
(LD)-based tag SNPs were examined across the NPAS3
gene region, and both risk and protective interacting haplo-
types were identified in four regions that differed from
controls (n = 455) [19].
The Npas3 knockout mouse: a model for schizophrenia
Our hypothesis that NPAS3 variation may alter brain
function and contribute to schizophrenia is supported
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described the consequences of disrupting Npas3 and the
closely related Npas1 gene, followed by two descriptions
of the Npas3 knockout mice that are particularly rele-
vant to schizophrenia [9,20,21].
Behavioral abnormalities
A battery of behavioral and psychological tests was ad-
ministered to the mice. A comparison of wild type
mice (Npas1+/+ Npas3+/+) with all possible genetic
combinations revealed significant differences in rela-
tion to three specific genotypes: Npas1−/− Npas3−/−,
Npas1−/− Npas3+/− and Npas1+/+ Npas3−/−. The knock-
out combinations showed a spectrum of behavioral and
neurological abnormalities, implicating a role for defects
in both genes in the development of schizophrenia. Behav-
ioural abnormalities included diminished startle response,
as measured by pre-pulse inhibition, gait defects, in-
creased open-field activity, and impaired social recogni-
tion. These changes were more apparent in the Npas3
null mice. An inability to prepare a nest or care for a litter
and stereotypic darting behavior were observed exclusively
in Npas3−/− mice [20,21].
Structural and biochemical changes
In the adult mouse brain, Npas1 and Npas3 are expressed
in inhibitory interneurons, which are essential to the cor-
rect processing of complex information received by the
brain. A marked decrease in the expression of reelin was
evident in inhibitory interneurons in Npas1+/− Npas3−/−
and Npas1−/− Npas3−/− mice. Reelin is critical for the nor-
mal patterning of the embryonic brain that guides new
neurons to specific locations in the appropriate layer of
the developing cortex, and may have synaptic signalling
functions in GABAergic interneurons [20]. Severe reduc-
tions in neural precursor cell proliferation in the hippo-
campal dentate gyrus were observed in Npas3−/− mice,
which correlated with a specific thinning of the granular
layer of the dentate gyrus. The neurogenesis defect was re-
versible by electroconvulsive treatment [21,22]. Enlarge-
ment of ventricles was noted as well as altered foliation
patterns in the cerebellum, and MRI analysis revealed
changes in the midline crossing of the fibres of the corpus
callosum [9].
The analogy between humans with NPAS3-related
schizophrenia and mouse models of the illness might
not be straightforward, however. These mice have both
copies of the Npas3 gene deleted, while the first family
described has one defective gene, with the other pre-
sumed to be normal. In our case–control study, chromo-
some 14 is intact and the patients of interest usually
displayed some specific variation in only one of the two
alleles. Therefore, it is important to further assess the
impact of this genetic variation in humans.The larger genetic study (conducted at two different
sites in Canada) is currently expanding on our earlier
preliminary work examining NPAS3 variants in schizo-
phrenia. Participants are being recruited during early
phase schizophrenia (first episode) as well as during
chronic illness. The specific goals are: 1) to extend our
case control study; 2) to carry out extensive evaluation
of participants with schizophrenia; 3) to assess the asso-
ciation of NPAS3 variation with clinical presentation and
cognitive function; 4) to develop molecular assays to
measure NPAS3 variant function.
Neuroimaging the impact of NPAS3 variants
Based on evidence of abnormal temporal lobe develop-
ment in mice with Npas3 defects, our neuroimaging
focus of interest in human brain will be the medial tem-
poral region, which includes the hippocampal formation
[21,22]. We will use several magnetic resonance imaging
tools, including volumetrics, spectroscopy and measures
of transverse relaxation time constants, in order to in-
vestigate the relationship between NPAS3 genetic vari-
ation and human brain structure and function.
Transverse relaxation time constants
One neuroimaging measure that will be obtained relates
to a microstructural feature of the medial temporal region.
We will assess the transverse relaxation time constants of
N-acetylaspartate (NAA), a neurochemical located intra-
cellularly in mature neurons. In vivo concentration levels
of NAA are slightly higher in white matter brain regions
relative to gray matter regions [23]. Post-mortem studies
have demonstrated that NAA is synthesized in neurons,
transported into white matter cells and catabolized into
aspartate and acetate in oligodendrocytes via aspartoacy-
lase [24]. This neuroimaging index will provide an estima-
tion of intracellular structural density in the brain region
studied [25]. Transverse relaxation time constants are
dependent on the number of molecule-microenvironment
interactions: a greater number of interactions results in
shorter relaxation times of the molecules of interest.
Declines in in vivo transverse relaxation time con-
stants of NAA have been previously documented in rela-
tion to aging in healthy people [26], and also in relation
to psychiatric illnesses like schizophrenia in frontal and
parieto-occipital regions [25,27], as well as in a pre-
frontal region involving mainly white matter [28].
In terms of post-mortem studies, one study [29] found
reduced packing density of hippocampal neurons in
established schizophrenia, while other studies [30,31] re-
ported no abnormality in that regard. Hippocampal cell
size (a more subtle measure than cell packing density)
has been reported to be reduced in schizophrenia [32].
We will also assess the transverse relaxation time con-
stants of the regional water signal. This neuroimaging
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volving both intracellular (cell density) and extracellular
compartments (cell numbers) of the brain tissue of inter-
est. There are few reports of in vivo studies assessing cell
packing density of brain tissue in schizophrenia, and to
our knowledge, no study has assessed potential abnor-
malities in these neuroimaging indices in relation to ill-
ness duration or genetic variants. These novel data will
thus be useful in generating novel hypotheses in regards
to the underpinnings of schizophrenia.
Hippocampal volume
A second neuroimaging index that will be obtained is at
the level of macroscopic anatomy: a volumetric measure
of the hippocampal formation. Structural differences in
the brains of schizophrenia patients have been summa-
rized in a meta-analysis that included 15 structural stud-
ies of schizophrenia [33]. The left temporal lobe (medial
region) was the most consistent brain region observed
with reduced volumes in schizophrenia (relative to
healthy controls), although 30% of these studies did not
report volumetric differences in this brain region. An
analysis of the same measure linked to genetic features
of patients, such as their NPAS3 genotype, might help to
clarify the basis for this variability.
A review of structural studies in schizophrenia [34]
also pointed to the temporal and hippocampal regions,
among others that might be altered in schizophrenia,
with no overall evidence for progression of alterations
over the course of illness or for sensitivity to medication
status. The large variability and quality of methods used
among studies was identified as a confounding factor
leading to variable results. In the proposed study, man-
ual editing and delineation of hippocampal volumes will
be performed as the final step in hippocampal measure-
ments in order to insure high validity. A previous report
suggested that manual volume segmentation has greater
validity relative to automated methods in accurately
assessing volumes of small subcortical structures [35].
Proton magnetic resonance spectroscopy (1H-MRS)
A third neuroimaging measure will involve regional con-
centration levels of visible neurochemicals acquired with
1H-MRS. Although not a specific focus of this study, the
1H-MRS spectral profiles to be acquired for the calcula-
tion of transverse relaxation time constants of NAA will
also provide information about regional concentration
levels of NAA, choline compounds (Cho), and creatine
plus phosphocreatine (tCr).
Previous 1H-MRS studies of schizophrenia assessing
the temporal region have reported mixed and inconclu-
sive results. Data compiled from studies with sample
sizes greater than 20 patients with established schizo-
phrenia, and that referenced neurochemicals to internalwater, reported reduced regional levels of NAA [36-38],
Cho and tCr [39] compared to controls. On the other
hand, several other well-designed 1H-MRS studies of pa-
tients with schizophrenia have observed normal concen-
tration levels in the temporal region for NAA [39-42],
Cho and tCr [36,38,41,42]. In patients with first episode
psychosis, normal concentration levels of all 1H-MRS
visible neurochemicals have been reported in the tem-
poral region [43,44]. In sum, despite some evidence for
reduced concentration levels of NAA, Cho or tCr in the
temporal region of patients with schizophrenia, there
are also numerous negative reports from well-designed
studies.
Presentation of the hypotheses
This neuroimaging study will evaluate the hypothesis
that the severe reductions in neural precursor cell prolif-
eration in the hippocampal dentate gyrus observed in
Npas3−/− mice will also be present to some degree in
those patients with schizophrenia displaying NPAS3 gen-
etic defects, and less so in other patients.
More specifically, we expect:
a) to replicate findings of reduced transverse relaxation
time constants of NAA previously found in other
brain regions [25,27], and of reduction in
macroscopic structural volumetric measures
previously found in the temporal region [33];
b) to observe greater levels of deviation from normal
values in neuroimaging indices for the subgroup of
patients displaying a defect in the NPAS3 gene,
relative to patients who don’t display this genetic
variation (previously unstudied);
c) to observe a greater magnitude of abnormalities in
neuroimaging indices measured at the micro-cellular
level (transverse relaxation time constants) relative
to the indices measured at the macro-anatomical
level (previously unstudied);
d) to observe an association between degree of
abnormality in brain measures and duration of
illness, in patients displaying the genetic defect
(previously unstudied).
Testing the hypothesis
A. The larger, two-site genetic study
We are currently completing a nationally funded genetic
study at two different sites, in order to extend our previ-
ous case control study and continue the evaluation of
the NPAS3 gene in schizophrenia. The genetic study in-
volves an extensive battery of clinical and cognitive as-
sessments, along with genetic data collection (from
saliva samples). Full ethics approval has been obtained
for both sites and patients are currently being enrolled
in the study, while a pool of DNA samples from
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control data.
At the specific site where the neuroimaging arm will
take place (Halifax), 150 patients will be recruited over
three years for the larger genetic study. About half of
these patients will be at the early stages of the illness
(<5 years since diagnosis) while the other patients will
have chronic illness.Statistical power analyses
In the previous case control study, we found significant dif-
ferences between patients and healthy controls for some
common NPAS3 variants. For example, some variants oc-
curred at a genotype frequency of ~30% (heterozygotes) in
the schizophrenia population, compared with ~20% in
healthy controls [15]. We also identified rare sequence var-
iants, observed solely in the schizophrenia population, at a
frequency of 1.2 to 3.6%. If we assume that these variants
are disease-associated and occur at a similar frequency for
all groups with schizophrenia, we would expect to find the
more common NPAS3 alleles in 45/150 (~7/120 homozy-
gotes) in the cohort recruited at the location of the neuro-
imaging arm cohort, and detect rare NPAS3 variants in 2
to 5 individuals.B. The one-site neuroimaging arm
Sample
Patients previously and currently enrolled in the genetic
study (final n = 150) will be invited to participate in the
neuroimaging arm. Ethics approval has been obtained to
contact individuals who already participated in the gen-
etic study and to use their genetic data in this neuroim-
aging arm. At time of writing, 60 patients have been
enrolled in the genetic study with full attainment of
sample size expected.
Patients from the genetic study will be categorized in
two subgroups: those with (n = 45) or without (n = 105)
NPAS3 variants. We will use the available genetic data in
order to ensure a minimal sample size of 45 in each gen-
etic subgroup of patients in the neuroimaging protocol.
In addition, the neuroimaging study will recruit 60
healthy controls, for compilation of normative data with
respect to all relevant neuroimaging indices.
Healthy controls will be gender- and age-matched to
patients; will have no lifetime diagnosis of psychiatric
disorder; no first-degree relative with a diagnosis of
psychosis; and taking no prescribed medications. Pa-
tients will be taking stable antipsychotic medications
(these will be recorded and explored as potential con-
founding variables).
All participants will be Caucasian, will have no lifetime
history of illicit drug usage of any type except for min-
imal experimentation (less than 10 times usage), and willhave a history of alcohol usage generally in line with
Canada’s Low-Risk Alcohol Drinking Guidelines [45].Statistical power analyses
In terms of transverse relaxation time constants of NAA
in schizophrenia relative to healthy controls, we calcu-
lated from previous data [27] that a sample size of 31
participants per group will provide adequate power to
detect differences between independent groups, with a
two-tailed test at an alpha level of .05 and power of .8.
In terms of volumetric measures of the hippocampus,
no previous data exist with respect to subgrouping pa-
tients based on NPAS3 genotypes. Given that the sample
size planned for each group/subgroup (n = 45 each) is in
line with most previous structural neuroimaging studies
of schizophrenia [46], the subgrouping of patients on
genetic grounds is likely to increase homogeneity of
measurements within groups, and thus increase statis-
tical power relative to previous structural studies.
Finally, with respect to 1H-MRS concentration levels
quantified from spectra, a previous meta-analysis has
calculated that across studies a minimal sample size of
39 patients in each group was required for adequate
power to detect group differences in concentration levels
of NAA [47].Neuroimaging acquisitions
The anatomical images will be acquired with a 1.5 Tesla
scanner using a 3D T1 weighted SPGR sequence involv-
ing 180 isometric slices acquired sagitally at a resolution
of 1 mm with no interslice gap.
The brain volume of interest (VOI) is located in the
left mid-temporal region, encompassing a large part of
the hippocampal formation; its dimensions are 20 mm
(R/L) by 28 mm (A/P) by 16 mm (S/I). Precise anatom-
ical landmarks have been devised for reliable selection of
the VOI.
Acquisitions of 1H-MRS neurochemical signals will be
performed using a PRESS localization sequence with 80
acquisitions, time of repetition (TR) of 3 s and time of
echo (TE) of 80, 120, 180, 350, and 550 ms. For the in-
ternal water signal, parameters are 4 acquisitions at TR
of 10 s and TEs of 50, 60, 80, 120, 180, 350, 600, 800
and 1000 ms. Total duration of scanning will be approxi-
mately 75 min.
Relaxometry acquisitions for NAA start at a TE of
80 ms, in order to minimize the contribution from mac-
romolecules into the estimation of neurochemicals
(which would be present at shorter TE times). Relaxo-
metry acquisitions for the water files start at a TE of
50 ms, in order to minimize the contribution from the
myelin water signal into the estimations of CSF and tis-
sue water relaxation times [48].
Bernier et al. BMC Medical Genetics 2014, 15:37 Page 6 of 8
http://www.biomedcentral.com/1471-2350/15/37Neuroimaging offline analyses
The spectral profiles will be fitted using fitMAN [49]
with a 3-peak manual fit of the three main signals: NAA,
Cho, and tCr [50]. In order to inform future work, we
will compile all the data acquired even when not part of
the main research question. At 1.5 Tesla however, it is
impossible to meaningfully interpret findings from the
Cho signal, as the anabolic component (phosphocholine;
PC) cannot be resolved separately from the catabolic
component (glycerophosphocholine; GPC) of the total
choline signal. On the other hand the tCr signal can pro-
vide very interesting information in the context of its
decay at several different TEs. This signal contains two
different components: phosphocreatine (PCr) and creat-
ine (Cr), both involved in the energy equilibrium in
brain cells [51]. Since PCr has much shorter T2 time
constants relative to Cr [52], each individual component
of the tCr signal can, with this design, be evaluated sep-
arately in terms of group differences.
From the NAA signal decay in amplitude over several
TEs, the corresponding transverse relaxation time con-
stants will be estimated as a curve fit of a mono-
exponential decay [52]. Area under the water signal peak
is calculated from the frequency domain at each TE
using a MATLAB script. From the decrease in peak area
as a function of TE, the corresponding T2 relaxation
time constants are estimated as a curve fit of a two-
component exponential decay using the Curve Fitting
Tool in MATLAB [53]. The decay curve of water could
potentially involve three components: CSF (long T2), tis-
sue water (intermediate T2), and myelin water (very
short T2) [48]. With this study design, signals from mye-
lin water are mostly decayed at the echo times sampled;
the very short myelin component is therefore not identi-
fied by the fitting algorithm.
Neurochemical concentration levels will be estimated
at TE = 0 ms, using estimates of T1 and T2 time con-
stants for the various tissue types and the internal water
signal as a reference. Data will only be compiled in stat-
istical analyses if the following quality criteria are met:
uncertainty in the estimation of the fit (Cramer Rao
lower bounds) lower than 20%, signal-to-noise ratio
greater than 10, and no artifact present in the spectral
profile. Tissue type segmentation of the VOI will be per-
formed using the software packages FSL [54] and AFNI
[55]. These procedures are automated with a customised
script and are routinely used in our current 1H-MRS
studies.
Segmentation of brain images
We will use the FSL module, FIRST, for an initial auto-
mated segmentation of subcortical structures, including
hippocampus and amygdala. The image is first co-
registered with the MNI 152 T1-weighted standard braintemplate at 1 mm resolution. This co-registration is done
in two stages: first, using a 12 DOF affine registration and
second, another 12 DOF affine registration optimized for
subcortical structures by using an MNI-space subcortical
mask. Segmentation is done using a library of shapes of
the subcortical structures (based on 336 data sets manu-
ally segmented) to fit surface meshes of each structure to
the registered image. Following the registration and seg-
mentation, a boundary correction method is run to re-
move any overlap between structures in the native space.
The results are stored in individual files for each structure
as well as a single file that contains all the segmentations.
The hippocampus volume will be determined from this
file (FSL includes a utility to determine the volume of a
segmented file). Total brain volumes will also be acquired
for purposes of covariance with hippocampal volumes.
Manual revision and editing of the automated segmented
images will be performed in AFNI using an interactive 3D
display. This manual editing procedure will insure optimal
validity of volumetric measurements `[35]. Reliability of
manually edited volumetric measures will be assessed be-
tween two raters and a concordance coefficient of at least
0.9 will be required.
Planned statistical analyses
All statistical analyses will be performed with SPSS, and
the threshold for significance will be set at .05, two-
tailed. The Group factor will have 3 levels: patients with
or without any of the three studied NPAS3 genetic vari-
ants, and healthy controls. Potential Group differences
in transverse relaxation time constants (in ms) of NAA
and of regional tissue water will be assessed with a
multivariate analysis of variance (MANOVA), followed
by appropriate follow-up tests if the MANOVA is sig-
nificant. In order to detect potential Group differences
in regional concentration levels of the three visible 1H-
MRS neurochemicals, we will also compute a MANOVA
and appropriate follow-up tests if the MANOVA would
be significant. Volumetric measures of the hippocampal
formation will be contrasted between the three groups
using an ANOVA, followed by post-hoc tests if the
ANOVA would be significant.
Potential confounding variables could have an im-
pact on neuroimaging measures. These variables in-
clude age, gender, stage of illness, medication status, as
well as levels of psychotic symptoms, depression, and
anxiety. Detailed information about these variables is
collected as part of the current genetic study. Explora-
tory correlations will be computed between these vari-
ables and the neuroimaging measures in order to
search for potential associations. In the potential case
of an association between two relevant variables, ap-
propriate covariance or regression analyses would be
used.
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To our knowledge, this is the first in vivo neuroimaging
study investigating associations between NPAS3 genetic
variants and irregularities in the microscopic anatomy
(transverse relaxation time constants), macroscopic anat-
omy (hippocampal volumes) and neurochemical profiles
(1H-MRS) of the temporal region in schizophrenia. Ir-
regularities have been reported in Npas3 knockout mice
and are hypothesized to also occur in individuals with
schizophrenia. The implications of obtaining these pion-
eer data are to lead toward the discrimination of differ-
ent subtypes of patients based on biological features,
including genetic markers. Our hope is that in the near
future, treatments will be tailored to specific biological
subtypes in order to optimize outcomes.Ethics approval and financial support
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